HER2遺伝子変異陽性転移性非小細胞肺がんにおけるTrastuzumab deruxtecan(T-DXd; DS-8201)単群第2相試験(DESTINY-Lung01試験)の中間解析結果
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
First Author: Smit E, et al.